Skip to main content
ENDO 2026 Main banner

Adrenal (Excluding Mineralocorticoids)

SAT-492 - A Case of Adrenal Lymphangioma Presenting as A Rapidly Enlarging Cystic Incidentaloma in A 36-Year-Old Female

Saturday, June 13, 2026
9:30 AM - 4:30 PM CT
Location: ENDOExpo; Poster Floor

    Abstract Poster Presenter(s)

  • DR

    Daniah Rizwan, MD

    Resident, Internal Medicine
    Geisinger Wyoming Valley Medical Center
    Wilkes Barre, PA, United States

    • Co-Author(s)

  • Apoorv Nimbvikar, MD

    GEISINGER WYOMING VALLEY MEDICAL CENTER
    Wilkes Barre, PA, United States

  • MV

    Mihail Voica, MD

    Geisinger Wyoming Valley Medical Center
    Wilkes-Barre, Pennsylvania, United States

  • NA

    Neda Amini, MD

    Geisinger Wyoming Valley Medical Center
    WilkesBarre, Pennsylvania, United States

Disclosure(s):
Daniah Rizwan, MD: No financial relationships to disclose
Apoorv Nimbvikar, MD: No financial relationships to disclose


Background: Adrenal lymphangioma is an exceptionally rare, benign vascular malformation, often discovered incidentally. While typically asymptomatic and slow growing, its potential for significant enlargement can prompt surgical intervention due to mass effect or diagnostic uncertainty.

Case Presentation: A 36-year-old female with a known left adrenal cyst, stable at 3 cm in 2023, presented with a documented increase in size to 6.1 cm on follow-up MRI in 2025.

She reported occasional early satiety but was otherwise asymptomatic. Biochemical workup ruled out a functional adrenal tumor. The patient underwent an uncomplicated robotic-assisted left adrenalectomy.

Histopathological examination confirmed the diagnosis of a benign adrenal lymphangioma, supported by positive immunohistochemical staining for D2-40, CD31, and ERG.

Conclusion: This case underscores that even benign, non-functional lesions like adrenal lymphangiomas can exhibit rapid growth. It highlights the importance of serial monitoring for adrenal incidentalomas and affirms minimally invasive adrenalectomy as the treatment of choice for symptomatic or enlarging lesions, providing both definitive diagnosis and cure.

*Unless otherwise noted, all abstracts presented at ENDO must not be released to the press or the public until the date and time of presentation. For oral presentations, the abstracts are embargoed until the session begins. The Endocrine Society reserves the right to lift the embargo on specific abstracts that are selected for promotion prior to or during ENDO.*